TPO Antibodies: Evidence-Based Ways to Improve This Number
Thyroid peroxidase antibodies (TPO-Ab, sometimes called anti-TPO) are antibodies directed against thyroid peroxidase, the enzyme the thyroid gland uses to make thyroid hormone. A positive TPO-Ab test is the standard laboratory marker of autoimmune thyroid disease, most commonly Hashimoto's thyroiditis and, less often, Graves' disease. TPO-Ab is a marker of autoimmune activity against the thyroid, not a measure of thyroid function itself; TSH and free T4 tell you how the gland is actually performing.
The question worth answering is not "how do I get TPO antibodies to zero" but "does a falling titer change what happens to my thyroid." Complete normalization is uncommon and is not the treatment goal recognized by endocrinology guidelines. Selenium supplementation is the intervention with the most consistent trial support for lowering titers, vitamin D repletion and gluten-free diets in celiac-positive patients have smaller and less consistent supporting data, and levothyroxine treats the resulting hypothyroidism without reliably lowering the antibody itself. No intervention listed here is FDA-approved for the purpose of lowering TPO-Ab; all are used off-label or as supplements, and the evidence quality behind each one varies considerably.
What this article can and cannot establish
Established: TPO-Ab positivity identifies autoimmune thyroid disease and predicts a higher risk of eventually developing hypothyroidism than a negative result. Levothyroxine treats hypothyroidism but is not an antibody-lowering therapy. Biotin supplements can distort TPO-Ab and other thyroid immunoassay results.
Plausible but not settled: Selenium supplementation at commonly studied doses may lower TPO-Ab titers over months in some patients, based on multiple small-to-moderate randomized trials with mixed effect sizes. Correcting vitamin D deficiency and, in celiac-positive patients, strict gluten avoidance appear associated with lower titers in observational and small interventional studies.
Not established: That lowering the antibody number itself changes long-term thyroid failure risk, independent of thyroid function; that myo-inositol, low-dose naltrexone, elimination diets, or stress-reduction programs reliably lower TPO-Ab in controlled trials; and any precise percentage reduction you should expect from a given supplement, since the source studies behind those figures have not been independently verified for this article and should not be treated as confirmed numbers.
A note on the numbers in circulation online for this topic: many pages quote specific percentage reductions ("selenium lowers TPO-Ab by X%") tied to named trials. Several of the citations commonly attached to those numbers do not hold up when checked against the actual paper. This draft avoids repeating unverified precise figures and instead describes direction and general trial size where that is defensible, flagging where a reader or clinician should pull the primary paper before treating a number as fact.
What a TPO antibody result actually tells you
Most laboratories report a negative result below roughly 9 IU/mL, with reference ranges varying by assay platform, so always check the range printed on your own report rather than a generic cutoff. TPO-Ab positivity is common in the general population and does not by itself mean a person has symptomatic thyroid disease. A substantial proportion of TPO-positive people with a normal TSH remain euthyroid for years, though positive TPO-Ab does raise the annual risk of developing overt hypothyroidism compared with a negative result, and that risk is higher when TSH is already in the upper-normal range or borderline elevated. Higher antibody titers are generally associated with faster progression to thyroid failure than low-positive titers, though exact risk figures by titer band should be confirmed against a current guideline document rather than taken from a summary page.
Because of that risk gradient, a positive TPO-Ab in a patient with subclinical hypothyyroidism (TSH mildly elevated, free T4 normal) is one of the factors clinicians use to decide whether to start levothyroxine or watch and recheck. A negative TPO-Ab does not rule out thyroid disease; it just makes autoimmune thyroiditis less likely as the cause.
The trend across repeat testing, done roughly every 6 to 12 months when someone is actively trying an intervention, is more clinically useful than any single absolute value. A titer falling from very high to moderately high is a meaningful change in autoimmune activity even though it remains "positive."
Selenium: the best-studied intervention, with real caveats
Selenium is a cofactor for glutathione peroxidase and thioredoxin reductase, enzymes that protect thyroid tissue from oxidative stress generated during hormone synthesis. Several randomized controlled trials, including at least one larger multi-center European trial in patients with autoimmune thyroiditis, have tested selenium supplementation (commonly 200 mcg/day as selenomethionine or selenium yeast) against placebo and reported greater reductions in TPO-Ab in the selenium arm over 6 to 12 months. Earlier, smaller trials from Greece and Italy reported larger relative reductions, but smaller trials tend to overestimate effect size, and specific percentage figures from those trials should be verified against the original papers before being quoted as fact.
What is reasonably solid: selenium supplementation at doses around 200 mcg/day appears more likely than placebo to lower TPO-Ab titers over several months in people with baseline low-normal selenium status. What is not solid: whether this translates into less progression to hypothyroidism, and whether the effect persists with long-term use. Selenium has a narrow safety margin; doses above roughly 400 mcg/day risk toxicity (hair and nail brittleness, garlic breath odor, gastrointestinal upset), so supplementation should not be layered on top of a multivitamin and separate selenium product without checking total intake. Endocrinology practice guidelines have historically stopped short of a blanket recommendation for selenium in TPO-positive patients, citing the absence of large trials with hard clinical endpoints (progression to hypothyroidism, not just antibody titers) rather than antibody change alone.
Vitamin D repletion
Vitamin D deficiency is more common in people with Hashimoto's thyroiditis than in the general population in observational studies, and small interventional trials have reported drops in TPO-Ab after correcting deficiency with cholecalciferol. This is associative and mechanistically plausible (vitamin D has immunomodulatory effects) rather than proven causal. Claims that a specific threshold such as 40 ng/mL is required for antibody effects, including a widely circulated quote attributed to a named researcher, could not be independently verified for this draft and have been removed rather than repeated; a reader who wants that level of specificity should ask their endocrinologist to point to the primary trial.
A reasonable, low-risk approach for a TPO-positive patient with documented vitamin D deficiency is standard repletion to a normal 25(OH)D level (commonly 30-50 ng/mL, per your lab's reference range) using a typical cholecalciferol dose, monitored with follow-up labs, rather than aggressive supplementation to an unproven higher target.
Diet: gluten, celiac screening, and elimination diets
The link between celiac disease and autoimmune thyroiditis is well established, and clinicians commonly screen newly diagnosed Hashimoto's patients for celiac disease with tissue transglutaminase IgA. In patients who have both conditions, strict gluten avoidance is medically necessary for the celiac disease regardless of any thyroid antibody effect, and some studies have reported antibody improvement with adherence, though the proportion of patients who normalize should be checked against the primary literature rather than quoted as a fixed percentage.
For people without celiac disease, evidence for a gluten-free diet lowering TPO-Ab is thin. Small, uncontrolled observational studies of elimination diets (such as the Autoimmune Protocol) have reported antibody reductions and symptom improvement, but without a control group it is not possible to separate a true treatment effect from natural fluctuation, placebo response, or regression to the mean. A Mediterranean-style, anti-inflammatory eating pattern is a reasonable general recommendation on cardiovascular and metabolic grounds, but it has not been specifically trial-tested against TPO-Ab.
Iodine intake matters in both directions. Very high iodine intake (supplements, kelp, seaweed products) can worsen autoimmune thyroiditis by increasing thyroid peroxidase activity, while iodine deficiency impairs thyroid hormone synthesis. Ordinary dietary iodine from iodized salt and a normal diet is appropriate; iodine supplements are not a recommended strategy for TPO-positive patients without a specific reason.
Myo-inositol, low-dose naltrexone, and other emerging options
Myo-inositol combined with selenium has been tested against selenium alone in small Italian trials, with reported additional benefit for TPO-Ab and TSH normalization. The trials are small, and the specific effect sizes circulating online for this combination have not been verified for this article; treat this as a plausible adjunct with modest supporting data rather than an established therapy.
Low-dose naltrexone (roughly 1.5-4.5 mg nightly) is used off-label in some integrative practices for Hashimoto's, based on a small retrospective chart review rather than a randomized controlled trial. Retrospective, unblinded case series are prone to selection bias and cannot establish that the drug caused the antibody change. No placebo-controlled trial of LDN for Hashimoto's has been confirmed for this article. LDN requires a prescription, is usually compounded rather than commercially manufactured, and compounded preparations carry their own quality-control considerations that a prescriber should discuss directly.
Stress, sleep, and moderate exercise all have plausible immunomodulatory mechanisms and general health benefits, and poor sleep and chronic stress are biologically linked to inflammatory cytokine activity. Direct trial evidence that fixing these factors lowers TPO-Ab specifically is limited. They are reasonable to address for overall health regardless of antibody effect, but should not be sold as an antibody-lowering protocol on their own.
What does not reliably lower the number
Levothyroxine treats the hypothyroidism that autoimmune thyroid destruction causes, but trial evidence does not support it as a way to lower TPO-Ab titers in euthyroid or subclinically hypothyroid patients. Levothyroxine is not an immune-modulating therapy; it replaces the hormone the damaged gland can no longer make enough of.
Biotin supplements, common in hair, skin, and nail products, do not affect true antibody production but can distort many streptavidin-biotin based immunoassays, producing inaccurate thyroid antibody, TSH, and free T4 results. The FDA has issued guidance on biotin interference with laboratory tests, and the general recommendation is to stop biotin supplementation for at least 48 hours, or longer for high-dose products, before thyroid antibody testing. An unexpectedly abnormal result in someone taking biotin warrants repeat testing after a washout rather than an assumption that the underlying disease has changed.
A decision framework for TPO-positive patients
Use this to organize a conversation with your clinician rather than as a self-directed treatment plan.
| Situation | What the evidence supports | What it does not support |
|---|---|---|
| TPO-Ab positive, TSH normal, no symptoms | Annual TSH/free T4 monitoring; celiac screening if not already done; correcting a documented vitamin D deficiency | Starting levothyroxine now; assuming supplements will prevent progression |
| TPO-Ab positive, TSH mildly elevated (subclinical hypothyroidism) | Discussing with your clinician whether antibody positivity plus TSH trend supports starting levothyroxine, per standard endocrinology practice | Waiting indefinitely on supplements alone if TSH keeps climbing |
| TPO-Ab very high, wanting to try selenium | A 6-month trial of selenium (commonly around 200 mcg/day) with a recheck of TPO-Ab, TSH, and total selenium exposure from all sources | Doses above roughly 400 mcg/day combined from multiple products; expecting normalization |
| Vitamin D deficient and TPO-Ab positive | Standard repletion to a normal range with follow-up labs | Chasing an unverified "immune threshold" level of vitamin D |
| Newly diagnosed Hashimoto's | Celiac disease screening (tissue transglutaminase IgA) | Assuming a gluten-free diet will help without a celiac diagnosis |
| Considering LDN, high-dose myo-inositol, or an elimination diet | Discussing these as adjuncts with uncertain, mostly small or uncontrolled supporting data | Treating any of these as a substitute for thyroid function monitoring |
| Abnormal antibody or TSH result while taking biotin | Stop biotin for 48+ hours and repeat the test | Trusting the result while still taking a high-dose biotin supplement |
When to seek care sooner rather than later: new or worsening hypothyroid symptoms (fatigue, cold intolerance, weight gain, constipation, hair thinning), a rapidly rising TSH, pregnancy or planning pregnancy with known TPO positivity (thyroid function needs closer monitoring in pregnancy), or a goiter or neck swelling. These situations need a clinician's evaluation rather than a supplement trial.
Reasonable next steps
A stepwise, low-risk approach that reflects the evidence above: confirm the TPO-Ab result and reference range, check TSH and free T4 to establish current thyroid function, screen for celiac disease if not already done, check and correct vitamin D deficiency if present, and discuss a time-limited selenium trial with your clinician if titers are high and selenium status is not already adequate. Recheck labs at 6 months. The goal is a stable or falling trend alongside preserved thyroid function, not a normalized antibody number, and levothyroxine remains the standard treatment once hypothyroidism is established regardless of what happens to the antibody titer.
Frequently asked questions
What is a normal TPO antibodies level?
What does a high TPO antibodies result mean?
What does a low or negative TPO antibodies result mean?
Can TPO antibodies be eliminated completely?
Does levothyroxine lower TPO antibodies?
Should I avoid gluten if I have high TPO antibodies?
Is iodine supplementation safe with high TPO antibodies?
How often should TPO antibodies be rechecked?
Can biotin supplements distort a TPO antibody result?
A note on evidence quality in this space: several precise percentage figures for selenium, vitamin D, myo-inositol, and diet interventions circulate widely online, frequently attached to specific trial citations. A number of those citation links, when checked, point to papers that do not match the claim. This draft has intentionally described trial direction and general size rather than repeating unverified numbers, and specific figures should be confirmed against the primary trial publication by a clinician or medical reviewer before being presented to patients as established fact.